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Abstract
Proteinase inhibitor PI9 (PI9) is an intracellular 42-kDa member of the ovalbumin family of serpins that is found primarily
in placenta, lung and lymphocytes. PI9 has been shown to be a fast-acting inhibitor of granzyme B in vitro, presumably
through the utilization of Glu340 as the P1 inhibitory residue in its reactive site loop. In this report, we describe the inhibition
of human neutrophil elastase by recombinant human PI9. Inhibition occurred with an overall KiP of 221 pM and a second-
order association rate constant of 1.5U105 M31 s31, indicating that PI9 is a potent inhibitor of this serine proteinase in vitro.
In addition, incubation of recombinant PI9 with native neutrophil elastase resulted in the formation of an SDS-resistant 62-
kDa complex. Amino-terminal sequence analyses provided evidence that inhibition of elastase occurred through the use of
Cys342 as the reactive P1 amino acid residue in the PI9 reactive site loop. Thus, PI9 joins its close relatives PI6 and PI8 as
having the ability to utilize multiple reactive site loop residues as the inhibitory P1 residue to expand its inhibitory
spectrum. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Human neutrophils provide host defense against
bacterial infection and are important in the elimina-
tion of pathogenic organisms in the lower respiratory
tract [1]. Neutrophil recruitment and accumulation,
usually identi¢ed by an increase in the number of
neutrophils in bronchoalveolar lavage, is associated
with such lung diseases as pneumonia, cystic ¢brosis,
adult respiratory distress syndrome, pulmonary ¢-
brosis, chronic bronchitis and asthma, and can result
in tissue damage from the release of neutrophil pro-
teinases, particularly elastase [1^7]. Human neutro-
phil elastase (HNE) is a 218-amino acid serine pro-
teinase located in high concentration within the
secretory granules of neutrophils, accounting for ap-
proximately 0.5% of the total cellular protein [8,9].
HNE demonstrates optimal proteolytic activity at
neutral pH towards a wide variety of substrates, in-
cluding coagulation factors, immunoglobulins, ¢bri-
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Abbreviations: HNE, human neutrophil elastase; RSL, reac-
tive site loop; K1-PI, K1-proteinase inhibitor; EI, human mono-
cyte/neutrophil elastase inhibitor; PAI-2, plasminogen activator
inhibitor-2; PI9, proteinase inhibitor 9; DMSO, dimethyl sulfox-
ide; DMF, dimethyl formamide; p-NPGB, p-nitrophenyl p-gua-
nidinobenzoate; S-2288, H-D-Ile-Pro-Arg-p-nitroanilide; MeO-
Suc-AAPV-pNA, MeOSuc-Ala-Ala-Pro-Val-p-nitroanilide; BSA,
bovine serum albumin; SDS, sodium dodecyl sulfate; PAGE,
polyacrylamide gel electrophoresis ; PBS, phosphate-bu¡ered sal-
ine
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nogen, ¢bronectin, proenzymes, receptors, structural
proteins, and selected proteinase inhibitors (reviewed
in [10]).
Due to the broad substrate speci¢city and potency
of HNE, serine proteinase inhibitors, or serpins,
must be present to regulate its proteolytic activity.
Serpins inactivate their target proteinases by mimick-
ing the substrate sequence recognized by the active
site of the proteinase to facilitate an initial loose
interaction, followed by the formation of a tight
1:1 stoichiometric inhibitory complex which is, in
most cases, resistant to denaturation [11]. During
the interaction, cleavage occurs between the P1 and
P1P amino acid residues in the serpin reactive site
loop (RSL), where the P1 residue is the major deter-
minant of the inhibitory speci¢city of the serpin, but
adjacent residues also contribute to the rate and
stability of the inhibition [12,13]. If the balance of
proteinase activity and proteinase inhibition is per-
turbed, the resulting unregulated proteinase activity
may be a causative factor in many pathological
events, such as those listed above. Since the turnover
of approximately 1011 neutrophils, containing ap-
proximately 50 mg of HNE, occurs daily, without
clinical evidence of uncontrolled tissue degradation
[9,14], the proteolytic activity of HNE must be
tightly regulated by one or more serpins, in order
to maintain tissue integrity. The three major inhibi-
tors of elastase in vivo are K1-proteinase inhibitor
(K1-PI), elastase inhibitor, and the low Mr inhibitors,
including antileukoprotease [15], secretory leukocyte
proteinase inhibitor [16] and ela¢n [17]. K1-PI, a ma-
jor serine proteinase inhibitor in plasma, is constitu-
tively synthesized in liver, as well as cells of epithelial
origin [18,19]. Individuals with de¢ciencies of K1-PI
are usually at risk for the development of pulmonary
emphysema from elastase-mediated degradation of
lung extracellular matrix [10]. Human elastase inhib-
itor (EI), a 42-kDa member of the ovalbumin family
of serpins found in monocytes, macrophages and
neutrophils, is also a potent inhibitor of elastase
[20,21]. EI utilizes Cys344 as the P1 residue in its
RSL to facilitate its interaction with HNE and the
formation of a 66-kDa SDS-stable elastase^elastase
inhibitor complex [22]. Finally, acid-stable inhibitors
of elastase (Mr V6^12 kDa) are synthesized by var-
ious secretory cells and are found in salivary gland
secretions, cervical mucus, seminal plasma and bron-
chial mucus [15,16,23].
Proteinase inhibitor 9 (PI9) is another 42-kDa
member of the ovalbumin family of serpins that
shares 49% sequence identity with EI and has re-
cently been shown to be a strong inhibitor of the
amidolytic activity of granzyme B, an apoptosis-in-
ducing serine proteinase contained within the gran-
ules of cytotoxic lymphocytes, as well as the bacterial
endoproteinase, subtilisin A [24^26]. PI9 is expressed
primarily in placenta and lung, but PI9 mRNA has
also been found in spleen, thymus, testis, bone mar-
row, and lymphocytes, primarily cytotoxic lympho-
cytes and B-cells [24,25]. In this report, we describe
the inhibition kinetics that characterize the inhibition
of HNE by PI9, an interaction that occurs through
the utilization of an alternative inhibitory residue in
its reactive site loop.
2. Materials and methods
2.1. Materials
Porcine trypsin was obtained from Novo Nordisk
(Bagsvaerd, Denmark). HEPES bu¡er, dimethyl sulf-
oxide (DMSO), dimethyl formamide (DMF), and
p-nitrophenyl p-guanidinobenzoate (p-NPGB) were
purchased from Sigma (St. Louis, MO). HNE, MeO-
Suc-Ala-Ala-Pro-Val-p-nitroanilide (MeOSuc-AAPV-
pNA), and K1-PI were purchased from Calbiochem-
Novabiochem (La Jolla, CA). H-D-Ile-Pro-Arg-p-
nitroanilide (S-2288) was purchased from Kabi Phar-
macia Hepar, (Franklin, OH). Recombinant human
PI9 was puri¢ed to homogeneity as described [24],
and its mass concentration determined by amino
acid analyses. Recombinant human neutrophil elas-
tase inhibitor, expressed in insect cells, was gener-
ously provided by Dr. Eileen Remold-O’Donnell
(The Center for Blood Research, Boston, MA). Ul-
traFit 3.0 software for regression analysis was ob-
tained from BioSoft (Ferguson, MO). IODO-GEN
was purchased from Pierce (Rockford, IL), and
Na125I was from DuPont/NEN (Boston, MA). Rab-
bit anti-HNE IgG were purchased from New Eng-
land Biolabs (Beverly, MA). 3,4-Dichloroisocoumar-
in were obtained from Boehringer Mannheim
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(Indianapolis, IN). A⁄-Gel 10 was purchased from
Bio-Rad (Hercules, CA). Human neutrophils were
kindly provided by Dr. Larry Sklar (University of
New Mexico, Albuquerque, NM).
2.2. General kinetic methods
The catalytically active concentration of porcine
trypsin was determined by active-site titration with
p-NPGB as described previously [27,28]. Subsequent
titrations were performed by pre-incubating enzyme
and inhibitor for 30 min at 37‡C in 20 mM HEPES
(pH 7.5)/0.15 M NaCl/0.01% BSA in wells of micro-
titer plates previously blocked with titration bu¡er
containing 0.1% BSA, followed by the addition of
substrate and measurement of the rate of substrate
hydrolysis at 405 nm using a UVmax kinetic micro-
titer plate reader (Molecular Dynamics, Menlo Park,
CA). Active-site titrated trypsin was used to titrate
the reactive concentration of K1-PI using S-2288 as
the substrate. Titrated K1-PI was then used to deter-
mine the catalytically active concentration of HNE
using MeOSuc-AAPV-pNA as the substrate.
The catalytic constants Km and kcat for HNE with
the substrate MeOSuc-AAPV-pNA were determined
at 25‡C in a solution of 20 mM HEPES (pH 7.5)/
0.15 M NaCl/0.01% BSA that contained 2% DMSO
and 1% DMF to ensure substrate solubility during
the reaction. Substrate hydrolysis was measured at
405 nm and the hydrolysis data were ¢tted to the
Michaelis^Menton equation using UltraFit software
to determine Km and kcat.
2.3. Slow binding inhibition kinetics
Progress curves were produced from data obtained
under pseudo ¢rst-order conditions by adding HNE
(1 nM ¢nal concentration) to a solution containing
MeOSuc-AAPV-pNA (1 mM ¢nal concentration)
and PI9 at various concentrations. The concentra-
tions of PI9 used to determine the kinetic constants
were 4, 8, 12, 16, and 20 nM. Substrate hydrolysis
was measured at 405 nm in UVT-acrylic cuvettes
previously blocked with 20 mM HEPES (pH 7.5)/
0.15 M NaCl/0.1% BSA in a Beckman DU-65 spec-
trophotometer equipped with a six-cell cuvette hold-
er, allowing multiple reactions to be monitored si-
multaneously. Reactions were started within 30 s in
0.5 ml of the bu¡er used to determine the catalytic
constants. Spontaneous substrate hydrolysis was
measured in separate experiments and was negligible.
The reactions were allowed to proceed at 25‡C until
steady-state velocity was attained. Data obtained
from each reaction were ¢tted to the integrated rate
equation for slow-binding inhibition [29]
A  vst vo3vs13e
3k0t
k0
 Ao 1
by non-linear regression using UltraFit software to
obtain values for the steady-state velocity (vs), the
initial velocity (vo), and the apparent ¢rst-order
rate constant (kP) for the establishment of steady-
state equilibrium of the proteinase^inhibitor com-
plex. The data obtained from non-linear regression
were used in graphical transformations to obtain val-
ues for the inhibition and rate constants for the in-
teraction of PI9 with HNE [29^34].
2.4. Detection of PI9-elastase SDS-stable complexes
HNE was radiolabeled with Na125I using the
IODO-GEN transfer method [35] to an average spe-
ci¢c radioactivity of 3.7 WCi/Wg. 125I-HNE (0.5 pmol)
was incubated with PI9 (0.7 nmol) for 30 min at
37‡C, after which the reaction mixture was boiled
in the presence of SDS and subjected to SDS-
PAGE under reducing conditions [36]. Following
electrophoresis, proteins were transferred to a
PVDF membrane by electroblotting for 45 min at
500 mA in 10 mM CAPS (pH 11) containing 10%
methanol. The membrane was washed in TBS, dried,
and subjected to autoradiography.
2.5. Amino acid sequencing
PI9 (500 pmol) and HNE (100 pmol) were incu-
bated in PBS at 37‡C for 30 min, followed by the
addition of 3,4-dichloroisocoumarin or PMSF to a
¢nal concentration of 1 mM to neutralize uninhibited
elastase. The reaction mixture was subsequently de-
salted and washed by centrifugation on a ProSpin
sample preparation cartridge (Perkin^ Elmer/ABI;
Foster City, CA), and sequenced in a Beckman
LF3000 protein sequencer.
BBAMCR 14521 3-9-99
J.R. Dahlen et al. / Biochimica et Biophysica Acta 1451 (1999) 233^241 235
3. Results
3.1. Determination of kinetic constants
The Km and kcat for HNE with MeOSuc-AAPV-
pNA were determined to be 233 þ 31 WM and 28 þ 1
s31, respectively. The kinetic characterization of the
inhibition of HNE by PI9 was performed using PI9
concentrations ranging from 4 to 20 times the molar
concentration of HNE. A family of progress curves
that are representative of the reaction between PI9
and HNE as a function of PI9 concentration are
shown in Fig. 1. Data obtained from the progress
curves were ¢tted to Eq. 1 by non-linear regression
to obtain values for vo, vs, and kP. The results indi-
cated that vo was inversely proportional to the inhib-
itor concentration at the selected PI9 concentrations.
The observation was con¢rmed by a plot of vmax/vo
as a function of PI9 concentration, which had a pos-
itive slope (data not shown). In addition, kP appeared
to increase as the PI9 concentration increased in the
reaction mixtures. There are three mechanisms that
can be used to describe the slow onset of inhibition
by a tight-binding inhibitor [28] :
P3
k1I
k31
PI mechanism A
P3
k1I
k31
PI 3
k2 slow
k32
PI0 mechanism B
P 3
k1 slow
k31
P03
k2I
k32
PI0 mechanism C
Mechanism A describes the single-step formation of
a complex of proteinase and inhibitor (PI). Mecha-
nism B is distinguished by the formation of the initial
PI complex, followed by the slow isomerization to a
tight PIP complex. In mechanism C, the proteinase
undergoes a slow isomerization to PP and then rap-
idly forms a tight PIP complex. Of the three mecha-
nisms, only mechanism B describes an inhibitory
mechanism in which the initial velocity is inversely
proportional to the inhibitor concentration. Further-
more, mechanism B also suggests that kP would in-
crease as the inhibitor concentration increases. Be-
cause the observations that were made ¢t these
criteria, the data obtained were treated in ways that
would facilitate the determination of kinetic con-
stants according to mechanism B.
The value for the equilibrium inhibition constant
for the initial loose interaction was calculated by ¢t-
ting the data obtained for the uninhibited control
reaction velocity, vmax, as well as the values for vo
and kP to the equation [27,29]
vmax
vo
 KmISKi 
Km
S  1 2
which describes a linear relationship. Linear regres-
sion analysis yielded a value for Ki of 8.1 þ 0.8 nM
(n = 4). To obtain the value for the overall equi-
librium inhibition constant, KiP, the equation
vmax
vs
 KmISKi 0 
Km
S  1 3
was used [27,29]. Eq. 3 describes a linear relationship
between vmax/vs and [PI9], with the value of vs being
inversely proportional to the inhibitor concentration.
The value for KiP was determined by linear regression
to be 221 þ 9 pM (n = 4). The second-order associa-
tion rate constant was determined by calculating and
Fig. 1. Progress curves from slow-binding kinetics for the inhib-
ition of HNE by PI9. HNE (1 nM) was reacted with 0, 4, 8,
12, 16, and 20 nM PI9 in 20 mM HEPES (pH 7.5)/0.15 M
NaCl/0.01% BSA/2% DMSO/1% DMF at 25‡C in the presence
of 1 mM MeOSuc-AAPV-pNA. The reactions were monitored
continuously for 5 h and the data were ¢tted to Eq. 1 to gener-
ate values for the variables vo, vs, and kP. To negate any e¡ects
of substrate depletion, the upper limit of product formation
used to determine the steady-state rates was within the linear
range of the uninhibited HNE control.
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plotting values of log([Pr]3[Pt]) versus time for the
initial 15 min of the reaction. The data obtained were
¢tted to the equation [30]
logPr3Pt  logPr30:43IkassocWt
1 S
Km
4
from which kassoc was determined to be
1.5 þ 0.5U105 M31 s31 (n = 4). The value for the
rate constant for the reverse isomerization step,
k32, was calculated directly from the slope of a
plot of kP versus vo/vs [31] to be 1.6 þ 0.2U1035 s31
(n = 4), which indicates a half-life of 12 h for the PI9/
HNE complex, according to the relationship
t1=2 = 0.693/k32. The value of the rate constant for
the formation of the tight complex, k2, was deter-
mined by ¢tting the data obtained for kP at selected
PI9 concentrations to the equation
k0  k32  k2
I
Ki
1 S
Km
 I
Ki
5
which predicts a hyperbolic relationship between kP
and [PI9]. Non-linear regression analysis using a Ki
value of 8.1 nM yielded a value for k2 of
6.6 þ 0.2U1034 s31 (n = 4). To verify that the inhib-
ition of HNE by PI9 occurs according to mechanism
B, a plot of 1/(kP3k32) versus 1/[PI9] was generated,
as shown in Fig. 2. This plot is linear for both mech-
anisms A and B, but the two mechanisms can be
distinguished by calculating the y-intercept of the
plot, which will cross the positive y-axis for inhibi-
tion according to mechanism B. The plot shown in
Fig. 2 was linear and crossed the positive y-axis at a
point approximately equal to 1/k2, which was calcu-
lated to be 4U1034 s31, and is reasonably close to
the value calculated according to Eq. 5.
3.2. Detection of PI9-elastase SDS-stable complexes
PI9 was incubated with 125I-HNE at an approxi-
mate molar ratio of 1400:1, the reaction was heat-
denatured with SDS, and electrophorized under re-
ducing conditions, as shown in Fig. 3. The addition
of PI9 to 125I-HNE resulted in the formation of an
SDS-resistant complex that migrated with an appar-
ent molecular mass of 62 kDa, along with an addi-
Fig. 2. 1/(kP3k32) versus 1/[PI9] for the interaction of PI9 with
HNE. Values for kP were generated as described in the legend
to Fig. 1. The value of k32 was determined from a plot of kP
against vmax/vs. The line crosses the positive y-axis at a point
approximately equal to 1/k2, as described for a two-step bind-
ing mechanism.
Fig. 3. SDS-stable complex formation between 125I-labeled
HNE and PI9. Complexes were allowed to form for 30 min at
37‡C, subsequently boiled, reduced and subjected to 10% SDS-
PAGE and electroblotting. Lane 1, HNE; lane 2, HNE+PI9;
lane 3, PI9.
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tional minor band that migrated with an apparent
Mr of 54 kDa.
3.3. Determination of the PI9 RSL cleavage site
A 500-pmol amount of PI9 was incubated with 100
pmol of HNE for 30 min at 37‡C, followed by the
addition of 3,4-dichloroisocoumarin or PMSF to
1 mM. N-terminal amino acid sequence analysis of
this reaction mixture yielded a sequence of Met-Glu-
Ser-Gly-Pro, corresponding to amino acids 343^347
located within the reactive site loop of PI9, thus in-
dicating that Cys342 is acting as the reactive center
residue for the inhibition of HNE (Fig. 4). In one
experiment where an active site inhibitor of elastase
was not included in the reaction mixture following
incubation of PI9 with HNE, a second minor se-
quence, Asn-Lys-Ala-Gly-Thr-Gln, corresponding
to amino acids 78^83 of PI9, was also observed.
The presence of this additional sequence suggests
that PI9 undergoes limited proteolysis by HNE at
an exposed site distinct from the reactive site loop
during preparation of the sample for sequence anal-
ysis.
4. Discussion
In the present study, we describe the kinetic mech-
anism for the inhibition of HNE by recombinant
PI9, which occurs through the use of an amino
acid residue in the RSL distinct from the predicted
P1 Glu340 residue. PI9 inhibited HNE via a two-step
mechanism with a Ki for the formation of the initial
loose proteinase^inhibitor complex of 8.1 nM, which
is similar to the Ki values of 8 and 6.6 nM for the
inhibition of plasmin and chymotrypsin by K2-anti-
plasmin, respectively [31]. The overall equilibrium
inhibition constant for this interaction was 221 pM,
which is comparable to the KiP for the inhibition of
chymotrypsin by K2-antiplasmin [31], as well as the
Ki value reported for the inhibition of human throm-
bin by PI8 [37]. The second-order association rate
constant for the inhibition of HNE by PI9 was cal-
culated to be 1.5U105 M31 s31, which is comparable
to the association rate constants reported for the in-
hibition of human thrombin by PI8 [37] and gran-
zyme B by CrmA [38], but exceeded the rates re-
ported for the inhibition of plasma kallikrein by
C1-inhibitor [39] and coagulation factor Xa by PI8
[37].
Amino acid sequence analysis provided suggestive
evidence that the residue used as the reactive center
in the reaction between PI9 and HNE was Cys342,
and not Glu340, as predicted through primary se-
quence alignments and as implied in the inhibition
of granzyme B, a serine proteinase that cleaves after
acidic residues [24,25]. A P1 Cys residue is also used
to facilitate the inhibition of HNE by EI, another
ovalbumin serpin [22]. In addition, both PI9 and
EI utilize the reactive center P1^P1P sequence of
Cys-Met for the inhibition of HNE. PI9, however,
does not share the potent inhibition of chymotrypsin
that has been demonstrated with horse EI [40]. This
apparent £exibility for the selection of P1 residues in
the reactive site loop may be a feature unique to PI6,
PI8, PI9, and K2-antiplasmin [41]. PI6 uses Arg341 as
its P1 residue for the inhibition of trypsin and throm-
bin, but uses Met340 for the inhibition of chymotryp-
sin [42]. In this connection, PI8 utilizes Arg339 as its
reactive center residue for the inhibition of human
thrombin, in contrast to Ser341, which is used to in-
hibit chymotrypsin [43]. To our knowledge, these
three serpins are the only ovalbumin-type serpins to
Fig. 4. Multiple reactive centers in the reactive site loop of PI9. Cleavage of the P1^P1P scissile bond occurs in the positions indicated
by the arrows. Amino acid residues in PI9 which act as reactive centers (P1 amino acids) are circled. The putative P1 residue used in
the inhibition of granzyme B is Glu340, while the putative P1 residue used for the inhibition of HNE is Cys342.g
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demonstrate this £exibility, suggesting that they may
represent a unique sub-family of ovalbumin serpins
evolutionarily similar to K2-antiplasmin that demon-
strate a broadened inhibitory speci¢city through the
use of multiple reactive centers in their reactive site
loop.
A second minor cleavage in PI9 occurred at a site
distinct from the RSL following incubation of PI9
with HNE. This second sequence was observed in
our initial RSL cleavage experiment, where an ac-
tive-site HNE inhibitor was not included after the
30-min incubation period. Although not known
with certainty, this minor cleavage is probably unre-
lated to the inhibitory mechanism, and most likely
represents an artifact related to the preparation of
the sample for sequence analysis as a result of cleav-
age of either free PI9 or the PI9^HNE complex by
free HNE. Of potential relevance, cleavage at this
site would decrease the apparent molecular mass of
the PI9^HNE complex by approximately 8 kDa,
which may explain the minor 54 kDa band seen in
SDS-PAGE/autoradiography following incubation
of 125I-HNE and PI9 (Fig. 3, lane 2) without the
subsequent addition of an HNE inhibitor.
The physiological signi¢cance of elastase inhibition
by PI9 is unclear. SDS-PAGE and immunoblot anal-
yses of human neutrophil cytosol preparations using
a⁄nity-puri¢ed rabbit anti-recombinant human PI9
IgG indicated the presence of a 42-kDa immunoreac-
tive band. Subsequent studies revealed that the a⁄n-
ity-puri¢ed anti-PI9 IgG preparation cross-reacted
weakly with recombinant human elastase inhibitor
(W. Kisiel, unpublished data), a 42-kDa serpin
present in neutrophils that shares 49% sequence iden-
tity with PI9, suggesting that the 42-kDa band ob-
served in immunoblots may represent a mixture of EI
and PI9. PI9 has been reported to be synthesized by
IL-2-stimulated peripheral blood mononuclear cells
[25], and it is possible that PI9, in concert with EI,
may play a role in the regulation of deleterious intra-
cellular proteolysis caused by aberrantly released
HNE in these cells. In addition, more recent studies
in our laboratory revealed the presence of PI9 anti-
gen and transcript in human umbilical vein endothe-
lial cells (HUVECs). Of potential importance, PI9
transcript levels were markedly upregulated (V10-
fold) in these cells following their stimulation with
the in£ammatory mediator, phorbol myristate ace-
tate (W. Kisiel, unpublished data). PI9, like PI8,
has two mRNA transcripts and shares a great deal
of primary sequence identity with the internal hydro-
phobic signal sequences found in ovalbumin and
PAI-2 [24,44]. Thus, it is conceivable that, in an in-
£ammatory state, some PI9 may be secreted by the
endothelial cell into the vascular basement mem-
brane to protect these cells from elastase-mediated
degradation of the matrix during neutrophil or tu-
mor cell extravasation. In this regard, the ability of
PI9 to be secreted by HUVECs is currently under
investigation in this laboratory, and these studies
may yield insight into the possible regulation of
HNE proteolysis by PI9 extracellularly.
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